SWP
JAZZ icon

Sagespring Wealth Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Sagespring Wealth Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Sell
907
-236
-21% -$51.7K ﹤0.01% 800
2026
Q1 		$216K Sell
1,143
-268
-19% -$46.8K ﹤0.01% 762
2025
Q4 		$240K Buy
+1,411
New +$216K ﹤0.01% 696

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Sagespring Wealth Partners's JAZZ Position: Q2 2026 in Review

Sagespring Wealth Partners reduced its Jazz Pharmaceuticals (JAZZ) stake by 21% in Q2 2026, selling an estimated $51.7K and leaving 907 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #800.

Sagespring Wealth Partners first reported a position in JAZZ in Q4 2025 and has held it in 3 quarters since. The position peaked at $240K in Q4 2025. 333 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Sagespring Wealth Partners held 907 shares of Jazz Pharmaceuticals worth $219K as of Q2 2026.
  • Sagespring Wealth Partners sold 236 Jazz Pharmaceuticals shares in Q2 2026, an estimated $51.7K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Sagespring Wealth Partners's portfolio in Q2 2026, its #800 holding.
  • Sagespring Wealth Partners first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Sagespring Wealth Partners's Jazz Pharmaceuticals position peaked at $240K in Q4 2025.
  • 333 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Sagespring Wealth Partners's 13F filing for Q2 2026, filed 3 Aug 2026.